Introduction: Polycythemia vera (PV) is a myeloproliferative neoplasm for which no curative treatment currently exists. However, the discovery of abnormally activated JAK/STAT signaling pushed the clinical development of JAK1/JAK2 inhibitors and other target drugs, including inhibitors of histone deacetylases (HDACi). Areas covered: We reviewed preclinical studies and clinical trials with givinostat, a Class I and II HDACi, through PubMed research and communications to the meeting of the most important hematology associations. Expert opinion: Proof of evidence has been obtained with givinostat earlier in JAK2V617F mutated cells and then in two clinical trials in patients with PV. Treatment resulted effective in inducing hematological response, symptomatic improvement and reduction of enlarged spleen, with good tolerability. Further clinical development is required to more clearly define the role of Givinostat in the therapeutic armamentarium of PV and exploit the full activity of the drug against the myeloproliferative clone. © 2014 Informa UK, Ltd.

Givinostat for the treatment of polycythemia vera / Pieri, L., Guglielmelli, P., Finazzi, G., Vannucchi, A.M.. - In: EXPERT OPINION ON ORPHAN DRUGS. - ISSN 2167-8707. - ELETTRONICO. - 2:(2014), pp. 841-850. [10.1517/21678707.2014.934223]

Givinostat for the treatment of polycythemia vera

Pieri, Lisa;Guglielmelli, Paola;Vannucchi, Alessandro M
2014

Abstract

Introduction: Polycythemia vera (PV) is a myeloproliferative neoplasm for which no curative treatment currently exists. However, the discovery of abnormally activated JAK/STAT signaling pushed the clinical development of JAK1/JAK2 inhibitors and other target drugs, including inhibitors of histone deacetylases (HDACi). Areas covered: We reviewed preclinical studies and clinical trials with givinostat, a Class I and II HDACi, through PubMed research and communications to the meeting of the most important hematology associations. Expert opinion: Proof of evidence has been obtained with givinostat earlier in JAK2V617F mutated cells and then in two clinical trials in patients with PV. Treatment resulted effective in inducing hematological response, symptomatic improvement and reduction of enlarged spleen, with good tolerability. Further clinical development is required to more clearly define the role of Givinostat in the therapeutic armamentarium of PV and exploit the full activity of the drug against the myeloproliferative clone. © 2014 Informa UK, Ltd.
2014
2
841
850
Goal 3: Good health and well-being
Pieri, Lisa; Guglielmelli, Paola; Finazzi, Guido; Vannucchi, Alessandro M
File in questo prodotto:
File Dimensione Formato  
14688-2014.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 478.55 kB
Formato Adobe PDF
478.55 kB Adobe PDF   Richiedi una copia all'autore

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1500354
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact